FDA clears targeted cholangiocarcinoma therapy
MDSpire News
September 24, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA approved lirafugratinib for adults with unresectable, locally advanced or metastatic cholangiocarcinoma with specific gene fusions.
Lirafugratinib is a kinase inhibitor administered at 70 mg once daily until disease progression or unacceptable toxicity.
The REFOCUS trial assessed lirafugratinib's efficacy, enrolling 116 patients previously treated with chemotherapy or chemoimmunotherapy.
In the trial, 46% of patients showed responses, with a median response duration of 11.8 months.
Safety warnings for lirafugratinib include ocular toxicity, hyperphosphatemia, soft tissue mineralization, and embryo-fetal toxicity.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: